Media & Resources

What’s missing in HIV vaccine development? If you guessed political will or buy-in from pharmaceutical companies, you’d be wrong. According to Fran Priddy, IAVI’s Chief Medical Officer, it’s actually the virus itself, she explained at AtlanticLIVE’s Vaccines + Immunity event on November 9 in Philadelphia. The event convened top health officials and vaccine experts from…

Two new discoveries by scientists with IAVI's Neutralizing Antibody Center at Scripps could have implications for development of both a vaccine and long-acting HIV prevention.

Natural-infection studies in Africa and India continue to inform HIV vaccine design.

A paper by IAVI's Devin Sok in Nature explores similarities between cow antibodies and HIV antibodies seen in humans.

IAVI scientists demonstrate how to produce a variety of HIV surface protein variants.

The International AIDS Vaccine Initiative (IAVI) expresses deep concern over drastic cuts to HIV/AIDS biomedical research and development proposed in the U.S. President’s FY 18 budget. This budget is built on the unfortunate fallacy that the AIDS epidemic can be sustainably controlled using current tools. The proposed 18 percent cut to the President’s Emergency Plan for AIDS Research (PEPFAR) limits capacity…

Canadian Institutes of Health Research funds Gary Kobinger to develop HIV vaccine in partnership with IAVI.

The world lost a leader in the fight against AIDS this week with the passing of Dr. Mark  Wainberg. The pioneering Canadian researcher is widely recognized for his involvement in the 1989 identification of antiviral drug Lamivudine, which is now one of the most extensively used drugs  in  treating  HIV  and its co-infections. “Dr.  Wainberg’s…